Evidence map›Paper›PMID 41849223›Full record

ArticleBriefings in bioinformatics2026

Biochemical-knowledge-driven machine learning pipeline for generating potent antimicrobial peptides.

Deliang Yang, Yifan Li, Chenxi Li, Qingpeng Zhang, Jiandong Huang, Xue Li, Peng Gao

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Deliang YangDepartment of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 102 Pok Fu Lam Road, Hong Kong SAR 00001, China.
Yifan LiDepartment of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 102 Pok Fu Lam Road, Hong Kong SAR 00001, China.
Chenxi LiApplied Oral Sciences & Community Dental Care, Faculty of Dentistry, The University of Hong Kong, 34 Hospital Road, Hong Kong SAR 00001, China.
Qingpeng ZhangDepartment of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Hong Kong SAR 00001, China.ORCID 0000-0002-6819-0686
Jiandong HuangSchool of Biomedical Sciences and School of Biomedical Engineering, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Hong Kong SAR 00001, China.ORCID 0000-0001-7531-2816
Xue LiDepartment of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 102 Pok Fu Lam Road, Hong Kong SAR 00001, China.ORCID 0000-0003-4836-7808
Peng GaoApplied Oral Sciences & Community Dental Care, Faculty of Dentistry, The University of Hong Kong, 34 Hospital Road, Hong Kong SAR 00001, China.ORCID 0000-0002-6877-6388

Funding

Collaborative Research Fund C7014-24GHKU Seed Fund for PI Research-Basic Research 2024/25 2402101729
6 · The paper itself

Abstract

The growing threat of antimicrobial resistance (AMR) necessitates the rapid discovery of novel antimicrobial peptides (AMPs) as alternative therapeutics. However, most computational approaches rely on binary AMP or non-AMP classification or permissive MIC thresholds (e.g. ≤128 μg/mL), offering limited biological interpretability and translational value. We present CVAE-BIO, a biochemical-knowledge-driven, multi-module pipeline for the discovery of AMPs targeting drug-resistant Escherichia coli as a model pathogen yet generalisable to other bacterial targets. The model integrates a conditional variational autoencoder (CVAE) constrained by key biochemical properties (MIC≤10 μg/mL, net charge > + 2, peptide length < 40 residues, instability index <40, and Boman index <0) with a Random Forest classifier trained on 30 biochemical descriptors. In vitro validation showed that 18.5% of generated peptides exhibited strong activity (MIC≤10 μg/mL), with 38.9% reaching MIC ≤50 μg/mL while maintaining key biochemical properties. Most validated novel peptides are narrow-spectrum AMP targeting E. coli. Wet-lab results also showed that highly active cationic-amphipathic AMPs are characterized by significantly low counts of tiny and small residues, suggesting that avoiding using these residues or limiting them to a maximum of 2 and 3, respectively, might improve the activity of AMP. Taking both antimicrobial activity and hemolytic toxicity into account, 9 peptides were identified as non-toxic and active AMP candidates. This explainable framework enables efficient AMP discovery under biochemical constraints and yields experimentally validated candidates with translational potential.

Indexed as

Antimicrobial Cationic PeptidesAntimicrobial PeptidesMachine LearningAutoencoderEscherichia coliMicrobial Sensitivity TestsPrediction AlgorithmsAntimicrobial Cationic PeptidesAntimicrobial Peptidesantimicrobial activity predictionantimicrobial peptidesbiochemical featurescationic-amphipathic AMPsconditional variational autoencodermulti-module pipeline

Identifiers

PMID41849223
PMCPMC12998437

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.